|
See related Sifrol information |
|
|
|
Manufacturer |
Boehringer Ingelheim |
|
Distributor |
Zuellig |
|
Contents |
Pramipexole |
|
Indications |
Idiopathic Parkinson's disease as monotherapy or in combination w/ levodopa. Symptomatic treatment of idiopathic restless legs syndrome.
Click to view Sifrol detailed prescribing infomation |
|
Dosage |
Sifrol Parkinson's disease Dose escalation: 0.125 mg tid on wk 1, 0.25 mg tid on wk 2, 0.5 mg tid on wk 3. Increase by 0.75 mg at wkly intervals if necessary up to max 4.5 mg/day. Maintenance: 0.375-4.5 mg/day. Patients on levodopa Reduce dose of levodopa. Restless legs syndrome 0.125 mg once daily 2-3 hr before bedtime; may be increased every 4-7 days to max 0.75 mg/day. Sifrol ER Parkinson's disease 0.375 mg on wk 1, 0.75 mg on wk 2, 1.5 mg on wk 3. Increase by 0.75 mg at wkly intervals if necessary up to max 4.5 mg/day. Maintenance: 0.375-4.5 mg/day. All doses to be taken once daily.
Click to view Sifrol detailed prescribing infomation |
|
Overdosage |
View Sifrol overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food (May also be taken w/ meals to minimise GI upset. ER tab: Do not chew/crush/divide.). |
|
Contraindications |
[Click for Sifrol detailed prescribing infomation] |
|
Special Precautions |
Renal impairment. Hallucinations & confusion. May impair ability to drive or operate machinery. Abrupt w/drawal. Severe CV disease. Monitor BP esp at the start of therapy & for melanoma. Childn & adolescent up to 18 yr. Pregnancy & lactation.
Click to view Sifrol detailed prescribing infomation |
|
Adverse Drug Reactions |
Abnormal behaviour eg binge eating, compulsive shopping, hypersexuality, pathological gambling. Abnormal dreams, amnesia, confusion, constipation, delusion, dizziness, dyskinesia, dyspnoea, fatigue, hallucinations, headache, hyperkinesia, hyperphagia, hypotension, insomnia, libido disorders, nausea, paranoia, peripheral oedema; pneumonia; pruritus, rash & other hypersensitivity; restlessness, somnolence, sudden onset of sleep, syncope, visual disturbance, vomiting, wt changes.
View ADR Monitoring Form |
|
Side Effects |
View Sifrol side effects |
|
Drug Interactions |
Drugs that inhibit active renal tubular secretion of cationic drugs eg cimetidine, amantadine. Other sedatives, alcohol.
View more drug interactions with Sifrol |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Sifrol storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Sifrol description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Sifrol mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
